PharmaShots Weekly Snapshots (November 07-11 2022)
Published: Nov 11, 2022 | Tags: NanOlogy, LSAM-PTX, Nonoperable Lung Cancer, Clinical Trial, P-IIa Trial
Published: Nov 11, 2022 | Tags: ImmunityBio, N-803, BCG, Bladder Cancer, Clinical Trial, P-II/III, QUILT 3.032 Trial
Published: Nov 11, 2022 | Tags: Takeda, Livtencity, maribavir, Post-Transplant Cytomegalovirus Infection, Regulatory, EC, Marketing Authorization
Published: Nov 11, 2022 | Tags: Parthenon, ImaginAb, PRTH-101, Anti-Cancer Therapies, CD8 ImmunoPET imaging technology, P-I trial, Pharma
Published: Nov 11, 2022 | Tags: Janssen, Tremfya, guselkumab, Active Psoriatic Arthritis, Clinical Trial, P-III, DISCOVER-2 Study
Published: Nov 11, 2022 | Tags: Pfizer, BioNTech, Omicron BA.4/BA.5- Bivalent Booster Vaccine, Regulatory, EMA, CHMP, Marketing Authorization
Published: Nov 10, 2022 | Tags: Minoryx Therapeutics, Neuraxpharm, leriglitazone, Rare Central Nervous System Disease, Pharma
Alvotech to Present Switching Study Results of AVT02, a Proposed Biosimilar to Humira at ACR 2022
Published: Nov 10, 2022 | Tags: Alvotech, AVT02, Biosimilar, Humira, Switching Study, Clinical Trial, ACR, 2022
Published: Nov 10, 2022 | Tags: ORYZON, Iadademstat, Neuroendocrine Carcinomas, Regulatory, US FDA, IND, P-II Basket Study
Published: Nov 10, 2022 | Tags: Novartis, Cosentyx, secukinumab, Enthesitis-Related Arthritis, Juvenile Psoriatic Arthritis, Regulatory, MHRA, Marketing Authorisation
Published: Nov 10, 2022 | Tags: Clearside Biomedical, CLS-AX, Neovascular Age-Related Macular Degeneration, Clinical Trial, P-I/IIa OASIS Trial
Published: Nov 10, 2022 | Tags: Novavax, Nuvaxovid, NVX-CoV2373, COVID-19, MHRA Recommendation, Conditional Marketing Authorization, Regulatory
Published: Nov 09, 2022 | Tags: AstraZeneca, Farxiga, dapagliflozin, Heart Failure, Ejection Fraction, Clinical Trial, P-III DELIVER Trial
Published: Nov 09, 2022 | Tags: Ocuphire Pharma, FamyGen, Nyxol Eye Drops, Reversal of Mydriasis, Presbyopia, Night Vision Disturbances, Pharma
Published: Nov 09, 2022 | Tags: Ipsen, Onivyde, fluorouracil, leucovorin, oxaliplatin, Metastatic Pancreatic Ductal Adenocarcinoma, Clinical Trial, P-III NAPOLI 3 Trial
Published: Nov 09, 2022 | Tags: Regeneron, Libtayo, cemiplimab-rwlc, Non-small Cell Lung Cancer, US, FDA, Approval
Sanofi Entered into a Research Collaboration with Insilico Medicine for ~$1.2B
Published: Nov 09, 2022 | Tags: Sanofi, Insilico Medicine, Pharma.AI, ~$1.2B, Pharma
Published: Nov 09, 2022 | Tags: MSD, Keytruda, pembrolizumab, Triple-Negative Breast Cancer, NICE Recommendation, Regulatory
Published: Nov 08, 2022 | Tags: Salipro Biotech, Sanofi, Discovery Programs, Salipro platform, License Agreement, Pharma
Published: Nov 08, 2022 | Tags: SciBase, Johnson & Johnson, AI-Based Solution, Skin Barrier Dysfunction, Electrical Impedance Spectroscopy technology, Pharma
Published: Nov 08, 2022 | Tags: Cyagen, Neurophth, AI-Designed AAV Gene Therapy Vectors, Ophthalmic Disorders, Biotech
Published: Nov 08, 2022 | Tags: Medtronic, Symplicity Spyral Renal Denervation System, SPYRAL HTN-ON MED Study, Hypertension, MedTech, Clinical Trial, AHA, 2022
Published: Nov 08, 2022 | Tags: Incyte, Mirati, INCB99280, Adagrasib, KRASG12C-Mutated Solid Tumors, Pharma
Published: Nov 08, 2022 | Tags: AbbVie, AGN-151607, Postoperative Atrial Fibrillation, Cardiac Surgery, Clinical Trial,P-II (NOVA) Trial
Asieris Reports the Completion of First Patient Dosing of Hexvix for the Treatment of Bladder Cancer
Published: Nov 07, 2022 | Tags: Asieris, Hexvix, Bladder Cancer, P-III bridging trial, Clinical Trial
Published: Nov 07, 2022 | Tags: ReCor Medical, Paradise Ultrasound Renal Denervation System, Hypertension, Medtech, RADIANCE Clinical Trial Program, AHA, 2022
Published: Nov 07, 2022 | Tags: NKGen Biotech, Parkinson’s Foundation, Natural Killer Cell Therapy, SNK01, Advanced Parkinson’s Disease, Pharma
Published: Nov 07, 2022 | Tags: Innovent, Tafolecimab, Non-Familial Hypercholesterolemia, Clinical Trial, P-III (CREDIT-1) Trial, AHA, 2022
Published: Nov 07, 2022 | Tags: Boehringer Ingelheim, Eli Lilly, Jardiance, empagliflozin, Chronic Kidney Disease, Clinical Trial, P-III, EMPA-KIDNEY Trial
Published: Nov 07, 2022 | Tags: Bayer, Aflibercept, Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, Clinical Trial, P-III, PULSAR, P-II/III, PHOTON Trial
Related Post: PharmaShots Weekly Snapshots (October 31 – November 04, 2022)
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.